JP2024511695A5 - - Google Patents

Info

Publication number
JP2024511695A5
JP2024511695A5 JP2023547047A JP2023547047A JP2024511695A5 JP 2024511695 A5 JP2024511695 A5 JP 2024511695A5 JP 2023547047 A JP2023547047 A JP 2023547047A JP 2023547047 A JP2023547047 A JP 2023547047A JP 2024511695 A5 JP2024511695 A5 JP 2024511695A5
Authority
JP
Japan
Prior art keywords
ophthalmic composition
topical ophthalmic
approximately
composition according
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023547047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511695A (ja
JP7749020B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014811 external-priority patent/WO2022169788A1/en
Publication of JP2024511695A publication Critical patent/JP2024511695A/ja
Publication of JP2024511695A5 publication Critical patent/JP2024511695A5/ja
Priority to JP2025157079A priority Critical patent/JP2025176201A/ja
Application granted granted Critical
Publication of JP7749020B2 publication Critical patent/JP7749020B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023547047A 2021-02-03 2022-02-02 局所眼科用組成物 Active JP7749020B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025157079A JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145091P 2021-02-03 2021-02-03
US63/145,091 2021-02-03
PCT/US2022/014811 WO2022169788A1 (en) 2021-02-03 2022-02-02 Topical ophthalmological compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025157079A Division JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Publications (3)

Publication Number Publication Date
JP2024511695A JP2024511695A (ja) 2024-03-15
JP2024511695A5 true JP2024511695A5 (https=) 2025-04-21
JP7749020B2 JP7749020B2 (ja) 2025-10-03

Family

ID=82741579

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023547047A Active JP7749020B2 (ja) 2021-02-03 2022-02-02 局所眼科用組成物
JP2025157079A Pending JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025157079A Pending JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Country Status (8)

Country Link
US (2) US12070501B1 (https=)
EP (1) EP4288151A4 (https=)
JP (2) JP7749020B2 (https=)
KR (1) KR20230142548A (https=)
AU (1) AU2022217160A1 (https=)
CA (1) CA3206612A1 (https=)
MX (1) MX2023009091A (https=)
WO (1) WO2022169788A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268457B (en) * 2019-08-04 2022-05-01 Omega 3 Galilee Ltd Oil- suspension of edible solids and methods of preparing the same
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN119789854A (zh) * 2023-08-04 2025-04-08 Ads医疗有限责任公司 用于递送眼科活性物的组合物和方法
WO2025131038A1 (en) * 2023-12-21 2025-06-26 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2026003129A1 (en) * 2024-06-26 2026-01-02 Novaliq Gmbh Stabilization of (r)-ruxolitinib

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE10030378A1 (de) 2000-06-21 2002-03-14 Audit Inst For Medical Service Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
US20100323978A1 (en) * 2009-06-22 2010-12-23 Calvin Hanna Non-aqueous oil delivery system for ophthalmic drugs
PL2547323T3 (pl) 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
CN102526051A (zh) * 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
CN113679699B (zh) * 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
CA2976952A1 (en) 2015-03-05 2016-09-09 Allergan, Inc. Self-emulsifying drug delivery system (sedds) for ophthalmic drug delivery
AU2017333420A1 (en) 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
BR112019012568A2 (pt) 2016-12-22 2019-11-26 Novaliq Gmbh composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias
PH12019501945B1 (en) 2017-02-21 2024-02-21 Singapore Health Serv Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
WO2018228975A1 (en) 2017-06-12 2018-12-20 Novaliq Gmbh Process for the preparation of semifluorinated alkanes using grignard reagents
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020152046A1 (en) 2019-01-21 2020-07-30 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
CA3128224A1 (en) * 2019-02-01 2020-08-06 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia
US11191751B1 (en) 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions

Similar Documents

Publication Publication Date Title
JP2024511695A5 (https=)
JP6440893B1 (ja) 半フッ素化アルカン組成物
JP6869336B2 (ja) シクロスポリンを含む眼科用組成物
JP4463681B2 (ja) 眼内使用のための非ポリマー親油性薬学的インプラント組成物
JP5654987B2 (ja) 日光角化症の処置のための局所用組成物
CN101808638A (zh) 抗真菌组合物
TW200934530A (en) Topical composition
RU2006115596A (ru) Твердые дозированные формы, включающие фибрат и статин
JP2012524771A5 (https=)
JP2023544853A5 (https=)
JP2004523609A5 (https=)
JP7506603B2 (ja) 局所用組成物
CN104602670A (zh) 含有ω-3 脂肪酸的眼用组合物
JPWO2017110874A1 (ja) 涙液油層安定化剤およびこれを含有する点眼剤
CN1909891A (zh) 药用组合物的微乳液
JP2024544415A5 (https=)
RU2007122470A (ru) Фармацевтические композиции, включающие производное камптотецина
WO1990013290A1 (fr) Composition pharmaceutique a base de paracetamol
RU2008105323A (ru) Консервирующая композиция для офтальмологического применения
ES2460967T3 (es) Método para la prevención de la degradación de una sustancia térmicamente inestable
JP5503939B2 (ja) アゼラスチン塩酸塩含有カプセル剤
ES2731151T3 (es) Composiciones oftálmicas basadas en ácidos poliinsaturados y triacilgliceroles
JPWO2022138826A5 (https=)
JPWO2022163686A5 (https=)
EP3700507A1 (en) Stable aqueous solutions comprising pufas